Synthesis and characterization of novel isoform-selective IP6K1 inhibitors

Michael M. Wormald, Glen Ernst, Huijun Wei, James Barrow

Research output: Contribution to journalArticle

Abstract

Inositol hexakisphosphate kinases (IP6Ks) have been increasingly studied as therapeutically interesting enzymes. IP6K isoform specific knock-outs have been used to successfully explore inositol pyrophosphate physiology and related pathologies. A pan-IP6K inhibitor, N2-(m-trifluorobenzyl)-N6-(p-nitrobenzyl) purine (TNP), has been used to confirm phenotypes observed in genetic knock-out experiments; however, it suffers by having modest potency and poor solubility making it difficult to handle for in vitro applications in the absence of DMSO. Moreover, TNP's pan-IP6K inhibitory profile does not inform which IP6K isoform is responsible for which phenotypes. In this report we describe a series of purine-based isoform specific IP6K1 inhibitors. The lead compound was identified after multiple rounds of SAR and has been found to selectively inhibit IP6K1 over IP6K2 or IP6K3 using biochemical and biophysical approaches. It also boasts increased solubility and IP6K1 potency over TNP. These new compounds are useful tools for additional assay development and exploration of IP6K1 specific biology.

Original languageEnglish (US)
Article number126628
JournalBioorganic and Medicinal Chemistry Letters
Volume29
Issue number19
DOIs
StatePublished - Oct 1 2019

Fingerprint

Protein Isoforms
Solubility
Lead compounds
Phenotype
Physiology
Pathology
Inositol
Dimethyl Sulfoxide
Assays
Enzymes
Experiments
purine
diphosphoric acid
inositol hexakisphosphate kinase
Lead
In Vitro Techniques

Keywords

  • Inositol hexakisphosphate kinase
  • Inositol pyrophosphate
  • Kinases
  • Selective enzyme inhibitors
  • Structure activity relationships

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Pharmaceutical Science
  • Drug Discovery
  • Clinical Biochemistry
  • Organic Chemistry

Cite this

Synthesis and characterization of novel isoform-selective IP6K1 inhibitors. / Wormald, Michael M.; Ernst, Glen; Wei, Huijun; Barrow, James.

In: Bioorganic and Medicinal Chemistry Letters, Vol. 29, No. 19, 126628, 01.10.2019.

Research output: Contribution to journalArticle

@article{15ed1ccf0e3048e487e5248a085442ef,
title = "Synthesis and characterization of novel isoform-selective IP6K1 inhibitors",
abstract = "Inositol hexakisphosphate kinases (IP6Ks) have been increasingly studied as therapeutically interesting enzymes. IP6K isoform specific knock-outs have been used to successfully explore inositol pyrophosphate physiology and related pathologies. A pan-IP6K inhibitor, N2-(m-trifluorobenzyl)-N6-(p-nitrobenzyl) purine (TNP), has been used to confirm phenotypes observed in genetic knock-out experiments; however, it suffers by having modest potency and poor solubility making it difficult to handle for in vitro applications in the absence of DMSO. Moreover, TNP's pan-IP6K inhibitory profile does not inform which IP6K isoform is responsible for which phenotypes. In this report we describe a series of purine-based isoform specific IP6K1 inhibitors. The lead compound was identified after multiple rounds of SAR and has been found to selectively inhibit IP6K1 over IP6K2 or IP6K3 using biochemical and biophysical approaches. It also boasts increased solubility and IP6K1 potency over TNP. These new compounds are useful tools for additional assay development and exploration of IP6K1 specific biology.",
keywords = "Inositol hexakisphosphate kinase, Inositol pyrophosphate, Kinases, Selective enzyme inhibitors, Structure activity relationships",
author = "Wormald, {Michael M.} and Glen Ernst and Huijun Wei and James Barrow",
year = "2019",
month = "10",
day = "1",
doi = "10.1016/j.bmcl.2019.126628",
language = "English (US)",
volume = "29",
journal = "Bioorganic and Medicinal Chemistry Letters",
issn = "0960-894X",
publisher = "Elsevier Limited",
number = "19",

}

TY - JOUR

T1 - Synthesis and characterization of novel isoform-selective IP6K1 inhibitors

AU - Wormald, Michael M.

AU - Ernst, Glen

AU - Wei, Huijun

AU - Barrow, James

PY - 2019/10/1

Y1 - 2019/10/1

N2 - Inositol hexakisphosphate kinases (IP6Ks) have been increasingly studied as therapeutically interesting enzymes. IP6K isoform specific knock-outs have been used to successfully explore inositol pyrophosphate physiology and related pathologies. A pan-IP6K inhibitor, N2-(m-trifluorobenzyl)-N6-(p-nitrobenzyl) purine (TNP), has been used to confirm phenotypes observed in genetic knock-out experiments; however, it suffers by having modest potency and poor solubility making it difficult to handle for in vitro applications in the absence of DMSO. Moreover, TNP's pan-IP6K inhibitory profile does not inform which IP6K isoform is responsible for which phenotypes. In this report we describe a series of purine-based isoform specific IP6K1 inhibitors. The lead compound was identified after multiple rounds of SAR and has been found to selectively inhibit IP6K1 over IP6K2 or IP6K3 using biochemical and biophysical approaches. It also boasts increased solubility and IP6K1 potency over TNP. These new compounds are useful tools for additional assay development and exploration of IP6K1 specific biology.

AB - Inositol hexakisphosphate kinases (IP6Ks) have been increasingly studied as therapeutically interesting enzymes. IP6K isoform specific knock-outs have been used to successfully explore inositol pyrophosphate physiology and related pathologies. A pan-IP6K inhibitor, N2-(m-trifluorobenzyl)-N6-(p-nitrobenzyl) purine (TNP), has been used to confirm phenotypes observed in genetic knock-out experiments; however, it suffers by having modest potency and poor solubility making it difficult to handle for in vitro applications in the absence of DMSO. Moreover, TNP's pan-IP6K inhibitory profile does not inform which IP6K isoform is responsible for which phenotypes. In this report we describe a series of purine-based isoform specific IP6K1 inhibitors. The lead compound was identified after multiple rounds of SAR and has been found to selectively inhibit IP6K1 over IP6K2 or IP6K3 using biochemical and biophysical approaches. It also boasts increased solubility and IP6K1 potency over TNP. These new compounds are useful tools for additional assay development and exploration of IP6K1 specific biology.

KW - Inositol hexakisphosphate kinase

KW - Inositol pyrophosphate

KW - Kinases

KW - Selective enzyme inhibitors

KW - Structure activity relationships

UR - http://www.scopus.com/inward/record.url?scp=85070919375&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070919375&partnerID=8YFLogxK

U2 - 10.1016/j.bmcl.2019.126628

DO - 10.1016/j.bmcl.2019.126628

M3 - Article

C2 - 31445853

AN - SCOPUS:85070919375

VL - 29

JO - Bioorganic and Medicinal Chemistry Letters

JF - Bioorganic and Medicinal Chemistry Letters

SN - 0960-894X

IS - 19

M1 - 126628

ER -